Sensitive and specific diagnostic and prognostic biomarkers for prostate cancer (PCa) are urgently needed. Urine samples are a non-invasive means to obtain abundant and readily accessible "liquid biopsies". Herein we used urine liquid biopsies to identify and characterize a novel group of urine-enriched RNAs and metabolites in PCa patients and normal individuals with or without benign prostatic disease. Differentially expressed RNAs were identified in urine samples by deep sequencing and metabolites in urine were measured by mass spectrometry. The mRNA and metabolite profiles were distinct in patients with benign and malignant disease. Integrated analysis of urinary gene expression and metabolite signatures unveiled an aberrant glutamate metabolism and tricarboxylic acid (TCA) cycle node in prostate cancer-derived cells.
Introduction
More than 180,000 men were diagnosed with prostate cancer (PCa) in the U.S. in 2016; 26,000 of these patients will die of the disease 1 . PCa is the second most frequently diagnosed cancer and the fifth leading cause of cancer deaths in men worldwide 2 . Although radiotherapy and surgery for localized PCa are effective, the prognosis for patients with advanced disease is poor. A test to detect PCa with high sensitivity and specificity at an early stage is a medical imperative.
Moreover, there is an urgent need for novel therapeutic approaches to manage this insidious and prevalent disease.
Serum prostate specific antigen (PSA) levels have been used for PCa diagnosis and screening for over thirty years, and digital rectal examination (DRE) for even longer 3 . However, PSA has poor sensitivity and specificity and does not distinguish indolent from aggressive cancers 3, 4 . Prostate cancer antigen 3 (PCA3), a prostate-specific non-coding RNA, was approved by the FDA in 2012 as the first PCa molecular diagnostic test for a specific clinical indication (need for repeat prostate biopsies in men aged >50 years with suspected PCa based on PSA levels and/or DRE and/or one or more previous negative biopsies) 5 . However, the value of the PCA3 test is limited by significant individual variability, better performance in the repeat biopsy setting, and conflicting data on the relationship between score and cancer grade using the most common threshold of 35 6 . Hence, there is a dire need for novel molecular diagnostic tools to more accurately detect and predict the behavior of localized PCa.
The kidneys produce urine to eliminate soluble waste from the bloodstream. Urine is an abundant biofluid for molecular or cellular analyses and is useful in the diagnosis and management of bladder, ovarian, and kidney diseases [7] [8] [9] . Urine contains over 2500 metabolites 10 5 and provides a window through which to view cellular biochemical reactions and intermediary metabolism. The metabolite signature in urine will reflect the impact of gene regulation, enzyme activities, and alterations in metabolic reactions occurring in the different cell types found along the urogenital tract.
Cancer cells exhibit perturbed metabolism that enables proliferation and survival 11 . Therefore, metabolomic profiling has been a fruitful approach for the identification of early cancer biomarkers 12, 13 . Furthermore, certain metabolic states are associated with prognosis in advanced cancers 13 . Several metabolomics studies have revealed PCa-specific metabolic phenotypes in serum, tissue, and urine 14, 15 . Indeed, an intermediate metabolite of glycine synthesis and degradation, sarcosine, has been described as a putative PCa biomarker in urine 16 . However, the utility of sarcosine as a biomarker is controversial and clinical validation has been elusive 17 .
Metabolomics data have been integrated with comprehensive gene expression analyses to better interrogate complex gene and metabolic networks. Integrating multiple aspects of biological complexity using different unsupervised approaches can help to pinpoint the most important and reproducible pathways driving biological processes and hence reveal robust biomarkers or promising drug targets 18, 19 . Here we performed metabolite profiling and high-throughput RNA sequencing of urine from patients with benign prostatic hyperplasia, prostatitis, and PCa. Our aims were to (a) discover cancer-specific changes in the urine with utility as sensitive and specific PCa biomarkers either alone or in combination and (b) identify novel drug targets for PCa. Importantly, our approach used single void urine samples (i.e., without prostatic massage) as proof-of-principle of how a simple urine specimen can be used for biomarker and target discovery. Integrated analysis of metabolomic and transcriptomic data from these liquid biopsies revealed a glutamate metabolism and tricarboxylic acid cycle node that was specific to prostate- 6 derived cancer cells and cancer-specific metabolic changes in urine. Functional validation in vitro provided mechanistic support for a pivotal role for GOT1-dependent glutamate metabolism in redox balance and cancer progression.
Results

Deep sequencing of urine-secreted mRNAs
Normal voided urine from men contains small numbers of exfoliated cells from different parts of the urinary tract including urothelial cells, squamous cells, renal tubular cells, and glandular cells including prostate epithelial cells 20 . PCa cells are shed into urine and can be successfully isolated, processed, and analyzed by various molecular techniques 3 , thereby providing a rich substrate for biomarker detection. We sought to exploit this readily accessible and copious substrate from PCa patients for biomarker discovery and, in turn, elucidate novel mechanistic aspects of PCa.
Quality output from current next-generation sequencing (NGS) technology depends on the availability of high-quality RNA. An initial challenge was that the quality and quantity of RNA extracted from the very small number of exfoliated cells in urine was poor 21 Figure 1) . To overcome the problem, we performed sequence-specific capture (Illumina TruSeq RNA Access) with the urine samples to reduce ribosomal RNA and enrich for exonic RNA sequences. With this approach, we successfully sequenced 11 PCa (for clinical details, see Supplementary Table 1 ), 12 normal, and one pooled set of three normal samples (combined due to individually low RNA yields). The 3825 RNA transcripts that were detected in 20 samples 7 readily but not perfectly segregated into normal and PCa groups (Supplementary Figure 2) . We concluded that RNA expression analysis of urine liquid biopsies by itself was unlikely to reveal sensitive and specific PCa biomarkers.
(Supplementary
We next identified cancer-specific gene signatures. Among 5510 differentially expressed transcripts, 4662 had reads per kilobase of transcript per million mapped reads (RPKM) values greater than one, and 116 transcripts (110 genes) were significantly up-or downregulated in PCa ( Table 3 ). To our knowledge, this is the first time that RNA-seq has been successfully applied to urine samples to profile coding genes.
Thirty-seven genes were significantly upregulated in PCa urine samples ( Table 1 and Figure 1a) compared to normal urine samples. To bolster confidence that the RNA originated from the patient's cancer rather than contaminating cells, we examined their expression in The Cancer Genome Atlas (TCGA) data (Figure 1b and Supplementary Table 4 ). Of these 37 genes, 35% (13/37) were significantly upregulated in primary tumors compared to normal (Figure 1b and   1c ). Three of these genes were transcription factors (ELK4, SMARCB1, BRD3) and six were known oncogenes (TFG, NACA, BRD3, ELK4, NPM1, RPL22) 22 . When quantified in two representative PCa cell lines (LNCaP and PC3), most transcripts were upregulated in both cell lines compared to normal prostate epithelial cells (PrEC) except for NACA (downregulated in both cell lines), BRD3 and EPCAM (decreased in PC3 cells), and HDAC6 (downregulated in LNCaP cells) (Figure 1d ). Gene set enrichment analysis (GSEA) revealed thirteen overrepresented pathways in PCa urine compared to normal urine samples based on normalized 8 gene set enrichment scores (NES) (Figure 1e ). Among them, the TCA cycle and alanine, aspartate, and glutamate metabolism were significantly enriched (Figures 1f and 1g ). This finding is highly consistent with current knowledge of prostate cancer disease progression using tissues and other biofluids 16, 22 . Taken together, our data suggest that the transcriptional profiles generated from cells residing in urine from PCa patients are likely to originate from cancerous prostate epithelial cells rather than other urinary tract contaminants.
Validation of urine gene signatures in tumor tissue
Since exfoliated cells in urine represent a mixture of cell types, we next established that the gene expression profiles of urine-exfoliated cells represented expression in prostate tissue using RNAseq data for 65 PCa and matched normal prostate tissues 23 ( Table 1) . Most of the 110 up-or downregulated genes in urine exfoliated cells agreed with tissue gene expression (Figure 2 and Supplementary Table 5 ). Of 37 upregulated genes, 34 genes were upregulated in PCa tissue, and 27 out of 34 genes (79%) were significantly upregulated (Figure 2) . For the downregulated genes, 46 out of 73 genes (60%) were downregulated in PCa tissue compared to normal tissue (Supplementary Table 5 ). These results suggest that the PCa gene signature detected in urine exfoliated cells represents a bone fide PCa signature, especially with regard to upregulated genes, which may therefore represent more robust biomarkers.
Thus, we performed principal component analysis (PCA) of the 37 upregulated genes in the 65 patient tissue RNA-seq data. This 37-gene signature divided the tumor samples into two distinct groups, A and B (Figure 3a) , which did not differ with respect to Gleason score, tumor stage, or metastasis status (Supplementary Figure 3) . However, the two groups did show significant 9 differences in PCA3 and KLK3 expression ( Supplementary Figure 4) , being significantly higher in group B than in group A patients (Supplementary Figure 4) .
With respect to pathway differences between groups, nine pathways were significantly different: eight pathways were significantly upregulated (FDR>0.05) in group B, and one pathway, olfactory transduction, was upregulated in group A (Figure 3b and 3c) . Therefore, the 37-gene signature in urine samples represents prostate tissue gene expression and might be useful to distinguish advanced PCa (higher PCA3 and KLK3 levels in cancer) as well as to detect PCa itself.
Metabolomic profiling of urine from normal subjects and patients with diseased prostates
Targeted or global strategies have been used to profile metabolites in urine samples and identify PCa biomarkers 14, 16, 24, 25 , but results have been highly variable 26 . In the first unbiased metabolomics study measuring 1126 metabolites in 262 clinical samples including 110 urine samples, the glycine derivative sarcosine was elevated in PCa tissue and urine from PCa patients, and functional validation of the oncogenic role of sarcosine was provided in vitro 16 . However, sarcosine was not a reproducible prognostic marker in independent cohorts 15, 17 , a common finding in single-biomarker studies that possess neither the specificity nor sensitivity for clinical development 27 .
With this in mind, we performed global metabolite profiling of urine from patients with normal prostates, benign prostatic hyperplasia (BPH), prostatitis (PTT), and PCa to discover cancerspecific metabolic changes. In global metabolite profiling, the metabolic profiles of urine specimens from normal subjects and patients with cancer were distinct and separate by PCA (Figure 4a and 4b) , whilst there was significant overlap between the profiles obtained from 10 patients with BPH and PTT (Figure 4c ). Positive and negative ion data were first normalized to the specific gravity and then normalized to the total ion signal for all subsequent statistical analyses (Supplementary Figure 5a ). Positive and negative ion data sets were treated separately, and initial analysis was performed with PCA. The negative ion data set separation by PCA was very distinct between PCa and control groups, with BPH and PTT clustering together but as a separate cluster from PCa and control. Separation was primarily observed along PC1 (Figure 4a ). However, no correlation was observed between PSA scores and metabolic profiling. Figure 5b) . Comprehensive metabolic networks in PCa urine samples have not been well studied, and understanding differential metabolic pathway utilization in PCa might contribute towards the development of robust biomarkers. Therefore, we performed metabolite-based pathway enrichment analysis (Supplementary Figure 5d ), which revealed 14 significantly impacted metabolic pathways in the urine metabolome (Figure 4d) . Notably, glutamate metabolism, TCA cycle metabolism, pyruvate metabolism, and several amino acids pathway metabolites were identified at higher levels in PCa urine samples compare to normal (Figure 4e) , consistent with previous tissue-based studies 16,23 .
This result was reproducible with a second set of urine samples (Supplementary
We next conducted metabolite-based urinary biomarker screening, with metabolite contribution assessed by examining the variable importance in projection (VIP) score, which is calculated from the weighted sum of the square for each partial least square design (PLS) loadings for each 11 principal component. Of the top twenty five variables identified by VIP scores, all were metabolite variables that significantly contributed to the class separation of normal and PCa samples (Figure 4f ). We then conducted multivariate receiver operating characteristics (ROC) curve-based exploratory biomarker analysis to identify a diagnostic PCa-related metabolite signature. To better predict PCa, the top 50 discriminatory metabolites were identified via logistic regression (Figure 4g) . A combination of six metabolites showed better discrimination (AUC>98%) than each metabolite individually (AUC<91%) (Figure 4g Figure 6a) .
Given that Gleason score (GS) status correlated with PCa tumor progression, an additional independent 11 normal, 11 GS-6, 11 GS-7, 11 GS-8, and 11 GS-9 PCa urine samples were collected and again subjected to global metabolomics analysis using mass spectrometry ( Figure   5 ). Metabolite data were analyzed using same statistical approaches as in Figure 4 . Furthermore, metabolome data accuracy were validated by PLS-DA-based Q2 model (Figure 5a ). Supervised multivariate statistical analysis of the global metabolome revealed a profound trend of clustering with respect to the four different GS groups and the normal urine samples (Figure 5b) .
Hierarchical clustering heatmap analysis identified distinct metabolic signatures among normal and different GS groups (Figure 5c ). Differential metabolite analysis revealed that most metabolites that were discriminatory across the normal and different GS group samples were involved in TCA cycle and glutamate metabolism (Figure 5d-i) . Notably, level of these metabolites were significantly increased with highest GS, the aggressive form of PCa (Figure   5d -i).
Prostate carcinogenesis is known to involve metabolic reprogramming to provide sufficient energy for rapid cellular proliferation 28, 29 . Many cancer cells exhibit augmented aerobic glycolysis, known as the Warburg effect, even in high-oxygen environments 30 . This metabolic adaptation helps provide essential cellular components such as lipids and nucleotides to support the anabolic needs of rapidly proliferating tumor cells. Beyond the Warburg effect, the TCA cycle and oxidative phosphorylation also play important roles in PCa 29, 31 . Prostate epithelial cells normally produce certain components of prostatic fluid such as citrate, PSA, and polyamines 31 .
Increased citrate production by prostate cells means that they favor citrate synthesis over citrate utilization. However, PCa cells degrade citrate and accumulate oxidized citrate, resulting in more efficient energy production 29, 32 .
Integrated gene expression and metabolite analysis
We reasoned that integrating changes in gene expression and metabolite levels evident in the urine samples would better reveal the key pathways driving PCa and hence pinpoint the most robust biomarkers. The integrated pathway analysis module of MetaboAnalyst 33 was used to map both genes and metabolites to KEGG pathways to determine not just overrepresented pathways, but also the relative importance of the genes and compounds based on their relative locations (topology). The top three pathways most significantly enriched for differentially expressed genes and metabolites were: aminoacyl-tRNA biosynthesis; Ala, Asp, and Glu metabolism; and the TCA cycle) (p<0.001; Figure 6a and Supplementary Table 6 ). Aminoacyl-tRNA biosynthesis probably represents an increase in global protein translation and demand for protein synthesis in cancer cells 34 . However, Ala, Asp, and Glu metabolism and the TCA cycle are closely related pathways that are critical for energy generation and carbon and nitrogen metabolism for biomass accumulation 28 , especially in rapidly dividing cells such as cancer cells. 13 Analysis of the top 25 metabolites identified by UHPLC-HRMS and their corresponding genes from RNA-seq revealed that GOT1-and GOT2-mediated metabolism was the main genemetabolite interactive node influencing Ala, Asp, and Glu metabolism and the TCA cycle metabolism (Figure 6b and Supplementary Figure 6 ). In several PCa clinical datasets, GOT1
expression was significantly higher in malignant prostate compared to normal, whereas GOT2 expression showed no significant differences (Figure 6c and 6d) . Interestingly, GOT1
expression was significantly elevated in high Gleason score tumors compared to controls (Figure   6e ). Therefore, GOT1-mediated glutamate metabolism might be critical for PCa disease progression, and a better understanding of GOT1-driven metabolism could reveal a potential drug target and biomarker for PCa.
Glutamate metabolism contributes to the cancerous phenotype via GOT1-mediated redox balance GOT1, a cytosolic transaminase that converts Asp to Glu, and other genes involved in Gln metabolism such as GLUD1, GOT1, GOT2, and MDH1 were significantly upregulated in PCa urine samples ( Supplementary Figure 7 and Supplementary Table 7 ). To investigate GOT1's role as a regulatory metabolic node in prostate cancer, we knocked down GOT1 in the prostate cancer cell lines LNCaP and PC3 using siRNA (Figure 7a ). As expected, GOT1 knockdown upregulated the upstream metabolites ( Supplementary Figure 7 and 8 (Figure 7b) , consistent with previous reports that GOT1 repression suppresses tumor growth 35, 36 and the invasiveness and colony forming ability of PC3 cells 14 (Figure 7c and 7d) . We therefore examined the mechanism by which GOT1 regulated prostate cancer cell viability.
Maintaining NAD/NADH balance supports de novo Asp biosynthesis and is required for proliferation 37, 38 . Since GOT1 is part of the malate-Asp shuttle 37 , we checked whether GOT1 knockdown affected the NAD/NADH ratio; the NAD/NADH ratio was indeed decreased ( Supplementary Figure 9 ), suggesting that this reduction may have influenced the cell proliferation inhibition in both LNCaP and PC3 cells. As depicted in Supplementary Figure 7 ,
GOT1 is necessary to convert Asp derived from the Gln TCA cycle into oxaloacetate and malate to produce NADPH 39 , which is essential for maintaining intracellular redox balance via detoxification of damaging reactive oxygen species (ROS). Both LNCaP and PC3 cells showed increased ROS levels upon GOT1 knockdown (Figure 7e ), suggesting that GOT1 plays a role in cellular redox balance and can be manipulated to reduce the viability of prostate cancer cells.
Discussion
Here we identified a group of putative RNA and metabolite biomarkers in urine and a novel therapeutic target in prostate cancer. To improve the accuracy of disease classification, we carried out metabolic and transcriptomic profiling of urine obtained from BPH, PTT, and PCa patients (without prostatic massage). Urine from normal healthy individuals was used as the control. Through an integrated analysis of metabolomic and transcriptomic data, we identified GOT1 as a key regulator of metabolic changes in PCa patients. 15 Recent advances in transcriptomics and metabolomics have led to the identification of various candidate biomarkers for cancer diagnosis and prognosis 16, 40 . However, biomarkers derived from one dataset may not be reliable, and reproducibility in independent cohorts is challenging 41 .
There are great advantages in using biofluids including blood, urine, saliva, and seminal plasma as sources of biomarkers 42, 43 . Among them, urine is a promising liquid biopsy as it is noninvasive, replenishable, and convenient to collect. Urine has been at the center of clinical proteomics and provided biomarkers for renal disease 44 , renal cell carcinoma 45 , bladder cancer 46 , and prostate cancer 47 . In addition to proteins and peptides, urine contains various nucleic acids, metabolites, and lipids. Recently, the long noncoding RNA PCA3 and the fusion gene TMPRSS2:ERG have been proposed as urinary PCa biomarkers 48 . Here we report for the first time a global transcriptomic profile of PCa in urine. We applied capture-based enrichment (RNA Access protocol), in which probes target exonic regions, and were able to separate PCa samples from normal healthy individual samples by unsupervised methods (Supplementary Figure 2) .
In pancreatic ductal adenocarcinoma (PDAC), the transaminase GOT1 is required to sustain cell growth by enabling the production of NADPH to compensate internal ROS ( Supplementary   Figure 7) . We showed that GOT1 is essential for prostate cancer cell line (PC3 and LNCaP) growth. GOT1 knockdown increased ROS levels, suggesting that GOT1 may be involved in NADPH generation. As reported previously, GOT1 also functions as a member of the malateaspartate shuttle 38 , in which two pairs of enzymes, glutamate oxaloacetate transaminases (GOT) and malate dehydrogenase (MDH), serve to transfer reducing equivalents across the mitochondrial membrane (Supplementary Figure 7) . Our transcriptomic analysis revealed the upregulation of all members of the shuttle including GOT1, GOT2, MDH1, and MDH2
( Supplementary Table 7 ). These results suggest that the malate-aspartate shuttle may play an 16 important role in cell growth in PCa. This hypothesis is supported by the reduction in NAD/NADH ratio upon GOT1 knockdown in both cell lines.
In conclusion, prostate cancers appear to undergo GOT1-dependent metabolic adaptation to promote a malignant phenotype and resist oxidative stress. The glutamate phenotype represented by the gene expression and metabolic changes in urine reflect this GOT1-dependent pathway in prostate cancer cells. In addition to focusing on these pathway components as biomarkers of prostate cancer in urine, enzymes involved in this pathway might be excellent targets for PCa therapy. Indeed, small molecule inhibitors of GLS1 (mitochondrial glutaminase), which converts glutamine to glutamate, already exist 49 . Targeting this pathway is worthy of further investigation either with or without concurrent ROS-induced cellular stress 49 , this latter approach a particularly appealing strategy in patients with prostate cancers treated with ionizing radiotherapy. Liquid biopsies are an extremely useful tool for non-invasive biomarker and target discovery.
Materials and Methods
Sample collection and preparation
Urine samples were collected from 20 benign prostatic hyperplasia (BPH), 11 prostatitis (PTT), Supplementary Table 8 . 19 
RNA access
The quantity and integrity of the RNA was measured using both the Qubit RNA HS Assay Kit on the mapping quality. The overall mapping rates were about 93%. mRNA quantification was conducted in Partek Genomics Suite 6.6. R package edgeR was used to analyze the differential expression of mRNAs.
Clustering and principal component analysis (PCA)
The resulting mRNA expression profile included 46,459 transcripts, and the non-parametric
Mann-Whitney U-test was used to identify significantly regulated transcripts. 5510 transcripts 20 were identified (p≤0.05) as significantly differentially expressed between normal and PCa groups. Within those 5,510 transcripts, 1,118 transcripts had RPKM values greater than 1.0 for all samples. We pre-compiled a gene panel that lists all prostate cancer-related genes (with the help of Illumina). By comparing with this panel, we obtained 542 transcripts with RPKMs greater than 1.0 for all samples. Within these 542, 116 transcripts were significantly regulated ( Table 1) . All overlapping transcripts between the expression profile and prostate cancer panel, a total of 3825 transcripts, were used to run the unsupervised clustering analysis and PCA.
Hierarchical cluster analysis was performed in R using the correlation between samples to characterize similarity. Initially, each sample was assigned to its own cluster and then the algorithm proceeded iteratively, at each stage joining the two most similar clusters and continuing until there was just a single cluster. Correlation between samples was calculated using the expression values of the 3825 transcripts. We also used PCA to visualize sample to sample distance. The transformation was defined that the first principal component accounted for the largest variance (as much of the variability in the dataset as possible). In the results, each sample was projected onto the 3D space in which the three axes were the first three highest principle components (see Supplementary Figure 2b ).
Gene set enrichment analysis (GSEA) of tissue RNA-seq data
Gene expression was analyzed in 65 patients using RNA-seq data 23 . Briefly, RPKM values from tumor and matched normal samples from 65 patients were analyzed using paired linear model differential expression analysis using the Bioconductor limma package 52 to find differentially expressed genes between tumor and matched normal. To compare between groups for tumor or matched normal tissues, linear model analysis using the limma package was used on RPKM values for all genes. The analysis was performed in R (version 3.4.4, www.R-project.org). 21 GSEA for KEGG pathways was conducted using the GSEA desktop application (borad.mit.edu/gsea). All genes were ranked using scores based on fold-change direction and pvalue, and enrichment analysis was conducted using GSEAPreranked with the 'classic' enrichment statistic. Significantly enriched genes sets were identified using q-value ≤ 0.05 as a cutoff.
Transient transfection and cell proliferation assay
Cells (0.3 x 10 6 cells) were mixed with siRNA (Thermo Fisher Scientific, final concentration 20 nM) and lipofectamine RNAiMAX (Thermo Fisher Scientific) mixture in 2 ml medium containing 10% FBS. Cells were plated in duplicate at 7500 cells per well into 96-well plates and, after 24 h, the medium was replaced. Cell proliferation was assessed using the CellTiter96
Aqueous One Solution Cell Proliferation Assay (MTS) kit (Promega, Madison, WI).
NAD and NADH quantification
NAD and NADH levels were measured using the NAD/NADH-Glo Assay kit (Promega). Cells were plated in duplicate (7500 cells per well) into 96-well plates. Cells were lysed with base solution (100 mM sodium carbonate, 20 mM sodium bicarbonate, 10 mM nicotinamide, and 0.05% Triton X-100) with 1% DTAB (Sigma, D8638). Lysates were heat-treated at 60ºC for 20 min in the presence/absence of acid. Heat-treated samples were then subjected to the luciferase assay according to the manufacturer's protocol and the NAD/NADH ratio was calculated.
Measurement of reactive oxygen species (ROS)
Cells (1 x 10 6 cells) were resuspended in 1 ml medium containing 20 uM 2'7'-dichlorofluoresicin diacetate (DCFH-DA) (Sigma, D6883) and incubated for 30 min at 37ºC in 5% CO 2 . Fluorescent cells were detected using a FACSCalibur flow cytometer (Becton Dickinson, Anaheim, CA) and
data were analyzed with the Software 2.5.1 from Flowing Software (www.flowingsoftware.com).
Invasion assay
The cell invasion assay was performed using Corning BioCoat Matrigel Invasion Chambers (Discovery Labware, Bedford, MA) according to the manufacturer's protocol. Briefly, cells were starved in serum-free medium for 24 h and plated into the upper chambers in serum-free medium (0.2 x 10 6 cells per chamber). Medium containing 10% FBS was added to the lower chambers.
Cells were incubated for 48 h at 37ºC. Invaded cells were stained with 0.5% crystal violet dye.
After washing the excess dye, cells were air dried. Methanol was used to extract dye from cells and optical density was measured at 570 nm.
Soft agar colony formation assay
To access anchorage-independent growth, a CytoSelect 96-well cell transformation assay kit (Cell Biolabs Inc., San Diego, CA) was used according to the manufacturer's protocol. Briefly, cells were seeded in soft agar at a density of 10,000 cells per well and incubated at 37ºC in 5% 34 anchorage-independent growth in prostate cancer cell lines upon GOT1 knockdown. (e) GOT1 knockdown significantly increases ROS production in PC3 and LNCaP cells. The data from three independent experiments were expressed as mean ± SD. 
